| Old Articles: <Older 5681-5690 Newer> |
|---|
 |
| AskMen.com |
The Upside Of Malaria New research is attempting the first live vaccine to fight malaria.   |
The Motley Fool
June 8, 2009
Brian Orelli |
For the RECORD... Avandia's not going to make a comeback for GlaxoSmithKline. |
Chemistry World
June 5, 2009
Anna Lewcock |
Pharma's new world order So-called 'pharmerging' markets will contribute over half of the growth of the global pharmaceutical market this year, according to market analysts. |
The Motley Fool
June 5, 2009
Brian Orelli |
Failure! Merck said today that rolofylline failed to show an effect in its phase 3 clinical trial in heart failure patients. |
The Motley Fool
June 4, 2009
Brian Orelli |
Ignore Icahn's Hoopla Carl Icahn and his fights with management at Biogen's Idec make for entertaining news coverage, but investors shouldn't spend too much time analyzing how the antics are going to affect the share price. |
The Motley Fool
June 4, 2009
Brian Orelli |
MegaMergers Going to the Dogs It looks like Merck isn't sure it'll be able to get its acquisition of Schering-Plough past regulators without doing a little trimming. |
InternetNews
June 3, 2009
Kenneth Corbin |
Privacy a Stumbling Block in Healthcare IT Government's push for universal electronic health records brings tech firms into thorny privacy debate. |
The Motley Fool
June 3, 2009
Brian Orelli |
No More Triple-Digit Returns? If FDA decisions could be predicted easily, investors might not get to enjoy triple-digit returns, so perhaps we shouldn't be too upset about the tight-lipped nature of the FDA. |
Chemistry World
June 2009
Derek Lowe |
Column: In the pipeline The author wonders about pharmaceutical companies' motives for collaboration |
The Motley Fool
June 2, 2009
Brian Orelli |
Pfizer: If You Can't Beat 'Em, Join 'Em Sutent fails. Again. |
| <Older 5681-5690 Newer> Return to current articles. |
